Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.
Glenmark Pharmaceuticals Presents New Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
March 5, 2018
Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
February 21, 2018
Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
February 16, 2018
Glenmark Pharmaceuticals Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
January 24, 2018
Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris™ in Patients with Perennial Allergic Rhinitis
December 13, 2017
Search Result :-Is an investigational new drug that has not been approved for commercial distribution in the United States.
US Media Contact
For media inquiries only, please contact An Phan, Corporate Communications.
For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.